loncastuximab tesirine
ADC Therapeutics 
['lymphoma', 'loncastuximab tesirine']
attending #eha2022? see research on health-related #qol and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large b-cell #lymphoma treated in a phase 2 clinical trial (lotis 2). 
From clinical to post-market - integrated #heor and #epi #research services for #pharma and #meddevice. Unit of @RTI_Intl. Non-profit. Like/RT?Endorsement